Genmab A+s

Christopher W L Chiu

Esther C W Breij

Tahamtan Ahmadi

Brian Elliott

Maria N Jure-Kunkel

Ida Hiemstra

Jenny Jianlin Chen

Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

Growing community of inventors

Warren, NJ, United States of America

Christopher W L Chiu